Corona Remedies Ltd reports sale of 4.58 million shares (7.5% of capital) by three investors

What Corona Remedies announced

On 18 June 2026, three investors – Sepia Investments Limited, Anchor Partners and Sage Investment Trust – notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) that they had sold a total of 4,580,891 equity shares of Corona Remedies Limited. The filing, submitted on 19 June 2026 at 07:11:14 UTC, is a disclosure required under Regulation 29(2) of the SEBI Substantial Acquisition of Shares & Takeovers (SAST) Regulations, 2011. The sellers acted in concert and are not part of the promoter group of the company.

The transaction does not involve any new acquirer; it simply records the reduction in shareholding by the three sellers. The shares sold were ordinary equity shares carrying voting rights and were listed on both BSE (scrip code 544644) and NSE (code CORONA).

Details of the share disposals

The combined sale of 4,580,891 shares therefore amounts to 7.49 % of Corona Remedies’ total voting share capital. After the disposals, the residual holdings of the sellers are:

• Sepia Investments: 7,755,786 shares (approximately 12.68 % of total capital).
• Anchor Partners: 290, -? (calculated as 451,853 – 161,861 = 289,992 shares, roughly 0.48 %).
• Sage Investment Trust: 161,400 shares (251,487 – 90,087 = 161,400, about 0.26 %).

These figures illustrate a material reduction in the stake of Sepia Investments, while the stakes of Anchor Partners and Sage Investment Trust remain modest.

Regulatory context – SEBI Regulation 29(2)

Regulation 29(2) of the SAST Regulations obliges any person who sells or acquires shares that together constitute 5 % or more of the total voting share capital of a listed company to disclose the transaction to the stock exchanges within two working days. The purpose is to ensure transparency in share‑holding patterns and to alert the market to any significant changes in control or influence.

In this case, each seller’s individual disposal is below the 5 % threshold, but the combined effect of the three sellers amounts to 7.49 %, thereby triggering the disclosure requirement. The filing includes a cover letter signed by the authorized representatives of each seller, confirming the number of shares sold and affirming that the sellers are acting in concert.

Key facts at a glance

Why this matters for investors

The disclosure does not indicate any change in control of Corona Remedies, as none of the sellers belong to the promoter group and the post‑sale holdings remain well below any statutory control thresholds. However, the reduction in the largest non‑promoter shareholder’s stake (Sepia Investments) may affect the composition of the non‑promoter block, which can be relevant for voting on matters that require a minimum non‑promoter quorum.

For existing shareholders, the transaction is a neutral event in terms of capital structure: no new shares were issued, and the total number of outstanding shares remains unchanged. Consequently, there is no immediate dilution of earnings per share or voting power for other shareholders.

Regulatory compliance is confirmed, as the sellers have filed the required notice within the stipulated timeline. The exchanges will update the shareholding pattern in their public records, and the information will be reflected in the next periodic share‑holding disclosures.

Conclusion

Corona Remedies Limited recorded the sale of 4,580,891 equity shares by Sepia Investments Ltd, Anchor Partners and Sage Investment Trust on 18 June 2026, amounting to 7.49 % of the company’s total voting share capital. The filing satisfies the disclosure obligations under SEBI’s Regulation 29(2) and has been accepted by both BSE and NSE. No further regulatory approvals are required, and the transaction does not alter the company’s control structure. Investors can expect the updated shareholding pattern to appear in the next public filing.

"The sellers have complied with SEBI’s SAST disclosure requirements, and the exchanges have taken the notice on record," the filing states.